top of page
“Review in hashtag#CellsCancer highlights the integration of SAAM II for PK-PD modeling by scientists from hashtag#Pfizer on their pipline" .”
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety: Cancer Cell
"Simone is presenting tomorrow at the LEAP Workshop ahead of CROI 2025 in San Francisco. He and his mentor, Rodney, will share updates on the Drug-Combination Platform Phase 1 clinical trial and the pharmaceutical platform enabling the long-acting transformation of small molecules. Simone leads DMPK and modeling efforts of the only non-profit drug development initiative currently in clinical stages for infectious diseases."​
https://www.croiconference.org/
“SAAM II is the official kinetic software used at the Joint EURADOS-ICRP Training Course on the Theory and Practical Application of Codes for the Determination of Dose After Internal Contamination.”
https://urlsand.esvalabs.com/?u=https%3A%2F%2Fwww.icrp.org%2Fadmin%2FEURADOS-ICRP_2024-Training-Course_RegistrationForm.pdf&e=2e1c2a42&h=bed6b47c&f=y&p=y
“Simone participated as invited panelist at the IWCPH in Liverpool on the role of modeling and simulation in advancing long-acting injectable products.”
International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2024 | AME (academicmedicaleducation.com)
"SAAM II may not be opening because of an interference caused by McAfee antivirus software. According to our recent investigations, a McAfee update has been found to block SAAM II from launching. To resolve this, you can create an exception for SAAM II within McAfee's settings."
​
"Simone is invited to speak at the 25th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiretroviral Drugs in Liverpool on 18-19 September"Title of the presentation "Modelling design and validations for complex Long-Acting Medicines"
Title of the presentation "Modelling design and validations for complex Long-Acting Medicines"
On Tuesday, July 23, Simone discussed the topic B8 Antiretroviral therapies and clinical issues in neonates, infants and children
Poster Exhibition
A novel physiologically-based pharmacokinetic (PBPK) model to guide pediatric dosing for a long-acting triple-drug-in-one injectable product candidate TLC-ART-101 (lopinavir/tenofovir/ritonavir)
1/2
Nanomath is pleased to inform you that it will participate again this year in the PAGE (Population Approach Group Europe) 2024 event, which will be held June 26-28, 2024 in Rome, Italy.
Simone conducted a SAAM II workshop at the University of Colorado Anschutz
1/5
Simone has presented at CROI in Denver about how modeling can provide more thought-through long-acting injectable solutions in children
https://www.croiconference.org/
1/5
New study out on drug-drug interaction and multiple dosing for long-acting injectables of nanoparticle
Directly from 31st PAGE Meeting 2023, second day of proceedings
1/4
Nanomath is pleased to inform you that it will be attending this year's PAGE (Population Approach Group Europe) 2023 event, which will take place from June 27 to June 30, 2023, in A Coruña, Spain.
SAAM II: Selected Software Use Cases in Modern PK-PD Data Analysis
Journal of Pharmaceutical Sciences
Outstanding early career scientists for 2022
Simone will speak about PBPK and nanoformulation in Seattle
February 18, 2023
Directly from AAPS 2022 PHARMSCI 360 Boston Convention & Exhibition Center.
Boston, MA
October 16-19, 2022
Emerging Role of Systems Pharmacology, Long-acting, & Targeted Drug-combination Tech in Making Therapeutic & Health Impact
Monday, October 2022 9-9:30 & 10-10:30 AM
Rethinking the Role of Clinical Pharmacology in a Systems Perspective to Accelerate Small Molecules (Entry, Protease and Polymerase Inhibitors) Development
Monday, October 17, 2022 3:45 PM – 4:00 PM
Two years anniversary from our President Interview at TG Leonardo in Italy. Those days marked the start of the pandemic. The interview had great relevance in Italy where it got more than 2 million view.
https://www.youtube.com/watch?v=7BpQthHGU0I
March 9th, 2022
Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism
Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles.
https://www.sciencedirect.com/science/article/pii/S0022354921005529?dgcid=coauthor
​
January 31th, 2022
​
Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism
Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture
https://www.sciencedirect.com/science/article/abs/pii/S0022354921005475?dgcid=coauthor
​
December 9th, 2021
​
Here an example of what we can offer. FDA Approves a New Dose of #INGREZZA (#Valbenazine) for Treatm.
The development program for this sNDA was facilitated via meetings under the Prescription Drug User Fee Act (PDUFA) VI Model-Informed Drug Development (MIDD) Paired Meeting Pilot Program. MIDD is an approach that involves developing and applying exposure-based, biological, and statistical models derived from preclinical and clinical data sources to inform drug development and decision-making. It aims to integrate information from diverse data sources to help decrease uncertainty and lower failure rates and to develop information that cannot or would not be generated experimentally. For additional information on the MIDD Paired Meeting Pilot Program, please visit https://go.usa.gov/xdtdP.
May 21th, 2021
Supporting the Development of Long-acting HIV Injectables via Pharmacokinetic Modeling.
Simone Perazzolo UW Pharmaceutics Research Associate in the Rodney Ho Lab, will be presenting on his research,
“Supporting the Development of Long-acting HIV Injectables via Pharmacokinetic Modeling.”
(Abstract attached)
​
November 9th, 2020
UW Pharmaceutics engineer discusses how HIV research could impact COVID-19 remendis
Rai Italyt Tg3 March 12th, 2020
bottom of page